Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443805 · ClinicalTrials.gov registry record · Phase 3
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
A Phase 3 study of Rhinitis, Allergic, Perennial and House Dust Mite Allergy, sponsored by Stallergenes Greer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,607
- Enrollment target
- 2
- Study locations
NCT02443805 is a Phase 3 study of Rhinitis, Allergic, Perennial and House Dust Mite Allergy that has completed, run by Stallergenes Greer. The registered enrollment target is 1,607 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02443805, a Phase 3 study of Rhinitis, Allergic, Perennial and House Dust Mite Allergy, has completed, sponsored by Stallergenes Greer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,607 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL 300 IR
Study Locations (2)
Florida
- University of South of Florida - Tampa
Other
- CHU Arnaud de Villeneuve - Montpellier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,607 participants |
| Start Date | 2015-09-29 |
| Est. Completion | 2018-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02443805
The ClinicalTrials.gov registry entry for NCT02443805 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,607 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stallergenes Greer, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rhinitis, Allergic, Perennial appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02443805 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Other.
Frequently Asked Questions
What is clinical trial NCT02443805 about?
NCT02443805 is a clinical study titled "Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR". The objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.
What is the current status of trial NCT02443805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,607 participants. The study started on 2015-09-29. Estimated completion is 2018-06-25.
What conditions does trial NCT02443805 study?
This clinical trial studies the following conditions: Rhinitis, Allergic, Perennial, House Dust Mite Allergy.
What interventions are being tested in trial NCT02443805?
The interventions under investigation include: Placebo (BIOLOGICAL), 300 IR (BIOLOGICAL).
Who is sponsoring clinical trial NCT02443805?
This trial is sponsored by Stallergenes Greer, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02443805 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhinitis, Allergic, Perennial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.